Comments on: UK’s NICE To Lift Ban On Kidney Cancer Meds http://www.pharmalot.com/2008/12/uks-nice-to-lift-ban-on-kidney-cancer-meds/ News, Comment and Conversation Fri, 10 Feb 2012 20:20:20 +0000 http://wordpress.org/?v=2.6.2 By: harry harrinordiquy http://www.pharmalot.com/2008/12/uks-nice-to-lift-ban-on-kidney-cancer-meds/#comment-383686 harry harrinordiquy Thu, 04 Dec 2008 17:00:59 +0000 http://www.pharmalot.com/?p=18091#comment-383686 I wonder which companies fund the Kidney Cancer patient group. I would question the 'brilliance' of all four products in that setting. Neither Avastin or Sutent have demonstrated increased overall survival in this indication and the best either Nexavar or Torisel can do is extend survival by four months compared with placebo. Should payers pay through the nose for drugs that only prove efficacy against a surrograte endpoint? If they should, they certainly won't for much longer. And four months extra versus placebo is hardly revolutionary. I wonder which companies fund the Kidney Cancer patient group. I would question the ‘brilliance’ of all four products in that setting.

Neither Avastin or Sutent have demonstrated increased overall survival in this indication and the best either Nexavar or Torisel can do is extend survival by four months compared with placebo.

Should payers pay through the nose for drugs that only prove efficacy against a surrograte endpoint? If they should, they certainly won’t for much longer.

And four months extra versus placebo is hardly revolutionary.

]]>